Summary
The prevalence of depression in the elderly suggests that a substantial number of older patients will be treated with an antidepressant medication such as one of the tricyclics, trazodone, fluoxetine or lithium. The physiological changes that accompany aging raise the possibilities of altered pharmacokinetics, patterns of efficacy and adverse effect profiles. The literature addressing the subject of antidepressant use in the elderly has not provided a clear, consistent picture of how these drugs behave in this population in comparison with younger patients. Particularly in the case of the tricyclic antidepressants (TCAs), a large degree of interindividual variation in drug clearance (CL) confounds attempts to find differences attributable to age per se. Study design, however, is also a problem in that very few investigators include a young control group, choosing instead to compare their data with previously reported outcomes. Designations of statistical significance and positive correlation also differ among investigators, and the clinical significance of any finding is not always addressed.
The available data suggest that imipramine CL is reduced in the elderly and that amitriptyline CL may be reduced. Desipramine CL does not appear to be affected by age, although decreased renal function in the elderly may lead to accumulation of the hydroxylated metabolite, the clinical importance of which is not known. Nortriptyline is the most thoroughly studied TCA in the elderly. CL seems decisively lower only in elderly patients with concurrent medical illness. The hydroxylated metabolite probably accumulates with diminishing renal function. Not enough data are available on doxepin to make a conclusion. Trazodone CL is diminished somewhat in elderly men. Lithium CL appears to diminish with the declining renal function associated with aging. Fluoxetine data are sparse. Available data do not show any decrease in CL of the parent drug; more information is needed on the metabolite norfluoxetine.
Although knowledge of CL changes with aging can help the clinician more accurately achieve the desired steady-state concentration of a drug during long term therapy, much work is still needed to evaluate the relationships among drug concentrations at steady-state, efficacy and adverse effects in the elderly.
Similar content being viewed by others
References
Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. Journal of Pharmacology and Experimental Therapeutics 232: 183–188, 1985
Abou-Saleh MT, Coppen A. The prognosis of depression in old age: the case for lithium therapy. British Journal of Psychiatry 143: 527–528, 1983
Alexanderson B. Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and multiple oral doses. European Journal of Clinical Pharmacology 5: 1–10, 1972
Antal EJ, Lawson IR, Alderson LM, Chapron DJ, Kramer PA. Estimating steady state desipramine levels in noninstitutionalized elderly patients using single dose disposition parameters. Journal of Clinical Psychopharmacology 2: 193–198, 1982
APA Task Force. Tricyclic antidepressants — blood level measurements and clinical outcome: an APA Task Force Report. American Journal of Psychiatry 142: 155–162, 1985
Bayer AJ, Pathy MSJ, Ankier SI. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly. British Journal of Clinical Pharmacology 16: 371–376, 1983
Benetello P, Furlanut M, Zara G, Baraldo M. Imipramine pharmacokinetics in depressed geriatric patients. International Journal of Clinical Pharmacology Research 10: 191–195, 1990
Bergstrom RF, Lemberger L, Fand NA, Wolen RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. British Journal of Psychiatry 153 (Suppl. 3): 47–50, 1988
Bjerre M, Gram LF, Kragh-Sørensen P, Kristensen CB, Pedersen OL, et al. Dose-dependent kinetics of imipramine in elderly patients. Psychopharmacology 75: 354–357, 1981
Blazer D. Depression in the elderly. New England Journal of Medicine 320: 164–166, 1989
Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. New England Journal of Medicine 313: 474–479, 1985
Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology 36: 537–547, 1989
Bupp SJ, Preskorn SH. The effect of age on plasma levels of nortriptyline. Annals of Clinical Psychiatry 3: 61–65, 1991
Burch JE, Ahmed O, Hullin RP, Mindham RHS. Antidepressive effect of amitriptyline treatment with plasma drug levels controlled within three different ranges. Psychopharmacology 94: 197–205, 1988
Carr AC, Hobson RP. High serum concentrations of antidepressants in elderly patients. British Medical Journal 131: 1151, 1977
Chapron DJ, Cameron IR, White LB, Merrall P. Observations on lithium disposition in the elderly. Journal of the American Geriatrics Society 30: 651–655, 1982
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41, 1976
Corona GL, Cucchi ML, Frattini P, Santagostino G, Schinelli S, et al. Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression. Psychopharmacology 100: 334–338, 1990
Cutler NR, Zavadil AP, Eisdorfer C, Ross RJ, Potter WZ. Concentrations of desipramine in elderly women. American Journal of Psychiatry 138: 1235–1237, 1981
Dawling S, Crome P, Braithwaite R. Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers. Clinical Pharmacokinetics 5: 394–401, 1980a
Dawling S, Crome P, Braithwaite RA, Lewis RR. Nortriptyline therapy in elderly patients: dosage prediction after single dose pharmacokinetic study. European Journal of Clinical Pharmacology 18: 147–150, 1980b
Dawling S, Crome P, Heyer EJ, Lewis RR. Nortriptyline therapy in elderly patients: dosage prediction from plasma concentration at 24 hours after a single 50mg dose. British Journal of Psychiatry 139: 413–416, 1981
deAngelis L. Lithium treatment and the geriatric population. International Journal of Clinical Pharmacology, Therapy and Toxicology 28: 394–398, 1990
Dumas C, Loi C-M, Cusack BJ. Hepatic drug metabolism and aging. Clinical Pharmacokinetics 19: 359–384, 1990
Ereshefsky L, Tran-Johnson T, Davis CM, LeRoy A. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine — new data and review. Clinical Chemistry 34: 863–880, 1988
Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. Journal of Clinical Psychiatry 46 (No. 3, Sect. 2): 20–25, 1985
Friedman JR, Norman DC, Yoshikawa TT. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. Journal of the American Geriatrics Society 37: 145–149, 1989
Fyrö B, Petterson U, Sedvall G. Pharmacokinetics of lithium in manic-depressive patients. Acta Psychiatrica Scandinavica 49: 237–247, 1973
Gerson SE, Plotkin DA, Jarvik LF. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. Journal of Clinical Psychopharmacology 8: 311–322, 1988
Glassman AH, Bigger JT, Giardina EV, Kantor SJ, Perel JM, et al. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1: 468–472, 1979
Gram LF, Søndergaard IB, Christiansen J, Petersen GO, Bech P, et al. Steady-state kinetics of imipramine in patients. Psychopharmacology 54: 255–261, 1977
Greenblatt DJ, Abernethy DR, Shader RL. Pharmacokinetic aspects of drug therapy in the elderly. Therapeutic Drug Monitoring 8: 249–255, 1986
Greenblatt DJ, Friedman H, Burstein ES, Scavone JM, Blyden GT, et al. Trazodone kinetics: effect of age, gender, and obesity. Clinical Pharmacology and Therapeutics 42: 193–200, 1987
Greenblatt DJ, Koch-Weser J. Clinical pharmacokinetics. New England Journal of Medicine 293: 702–705, 964-970, 1975
Greenblatt DJ, Koch-Weser J. Intramuscular injection of drugs. New England Journal of Medicine 295: 542–546, 1976
Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. New England Journal of Medicine 306: 1081–1088, 1982
Guttendorf RJ, Wedlund PJ. Genetic aspects of drug disposition and therapeutics. Journal of Clinical Pharmacology 32: 107–117, 1992
Halaris A. Antidepressant drug therapy in the elderly: enhancing safety and compliance. International Journal of Psychiatry in Medicine 16: 1–19, 1986
Hardy BG, Shulman KI, MacKenzie SE, Kutcher SP, Silverberg JD. Pharmacokinetics of lithium in the elderly. Journal of Clinical Psychopharmacology 7: 153–158, 1987
Harmatz JS, Greenblatt DJ. Falling off the straight line: some hazards of correlation and regression. Journal of Clinical Psychopharmacology 12: 75–78, 1992
Henry JF, Altamura C, Gomeni R, Hervy MP, Forette F, et al. Pharmacokinetics of amitriptyline in the elderly. International Journal of Clinical Pharmacology, Therapy and Toxicology 19: 1–5, 1981
Hewick DS, Newbury P, Hopwood S, Naylor G, Moody J. Age as a factor affecting lithium therapy. British Journal of Clinical Pharmacology 4: 201–205, 1977
Isaacson EI. Central nervous system stimulants. In Delgado & Remers (Eds) Wilson and Gisvold’s textbook of organic medicinal and pharmaceutical chemistry, 9th ed., pp. 395–411, JB Lippincott, Philadelphia, 1991
Janowsky DS, Byerley B. Desipramine: an overview. Journal of Clinical Psychiatry 45 (No. 10, Sect. 2): 3–7, 1984
Katz IR, Simpson GM, Jethanandani V, Cooper T, Muhly C. Steady state pharmacokinetics of nortriptyline in the frail elderly. Neuropsychopharmacology 2: 229–236, 1989
Kitanaka I, Ross RJ, Cutler NR, Zavadil AP, Potter WZ. Altered hydroxydesipramine concentrations in elderly depressed patients. Clinical Pharmacology and Therapeutics 31: 51–55, 1982
Koenig HG. Treatment considerations for the depressed geriatric medical patient. Drugs & Aging 1: 266–278, 1991
Kragh-Sørensen P, Larsen N-E. Factors influencing nortriptyline steady-state kinetics: plasma and saliva levels. Clinical Pharmacology and Therapeutics 28: 796–803, 1980
Kumar V, Smith RC, Reed K, Leelavathi DE. Plasma levels and effects of nortriptyline in geriatric depressed patients. Acta Psychiatrica Scandinavica 75: 20–28, 1987
Kutcher SP, Reid K, Dubbin JD, Shulman KI. Electrocardiogram changes and therapeutic desipramine and 2-hydroxy-desipramine concentrations in elderly depressives. British Journal of Psychiatry 148: 676–679, 1986
Leinonen E, Ylitalo P. The influence of ageing on serum levels of tertiary tricyclic antidepressants. Human Psychopharmacology 6: 139–146, 1991
Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, et al. Fluoxetine: clinical pharmacology and physiologic disposition. Journal of Clinical Psychiatry 46 (No. 3, Sect. 2): 14–19, 1985
Levi M, Rowe JW. Aging and the kidney. In Schreier & Gottschalk (Eds) Diseases of the kidney, pp. 2657–2679, Little Brown and Co., Boston, 1988
Mason RW, McQueen EG, Keary PJ, McQueen EG, Keary PJ, et al. Pharmacokinetics of lithium. Clinical Pharmacokinetics 3: 241–246, 1978
Mazoit JX, Sandouk P, Scherrmann JM, Roche A. Extrahepatic metabolism of morphine occurs in humans. Clinical Pharmacology and Therapeutics 48: 613–618, 1990
McCue RE, Georgotas A, Nagachandran N, Basir MA, Go EA, et al. Plasma levels of nortriptyline and 10-hydroxynortripty-line and treatment-related electrocardiographic changes in the elderly depressed. Journal of Psychiatric Research 23: 73–79, 1989
Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. New England Journal of Medicine 321: 303–309, 1989
Monteleone P, Gnocchi G, Delrio G. Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study. Journal of Clinical Psychopharmacology 9: 284–287, 1989
Murphy JM, Olivier DC, Monson RR, Sobol AM, Leighton A. Incidence of depression and anxiety. American Journal of Public Health 78: 534–540, 1988
Nelson JC, Atillasoy E, Mazure C, Jatlow P. Hydroxydesipramine in the elderly. Journal of Clinical Psychopharmacology 8: 428–433, 1988
Nelson JC, Jatlow PI, Mazure C. Desipramine plasma levels and response in elderly melancholic patients. Journal of Clinical Psychopharmacology 5: 217–220, 1985
Nielsen-Kudsk F, Amidsen A. Analysis of the pharmacokinetics of lithium in man. European Journal of Clinical Pharmacology 16: 271–277, 1979
Nies A, Robinson DS, Friedman MJ, Green R, Cooper TB, et al. Relationship between age and tricyclic antidepressant plasma levels. American Journal of Psychiatry 134: 790–793, 1977
Ogura C, Kishimoto A, Mizukawa R, Hazama H, Honma H, et al. Age differences in effects on blood pressure, flicker fusion frequency, salivation and pharmacokinetics of single oral doses of dothiepin and amitriptyline. European Journal of Clinical Pharmacology 25: 811–814, 1983
Peabody CA, Whiteford HA, Hollister LE. Antidepressants and the elderly. Journal of the American Geriatrics Society 34: 869–874, 1986
Plotkin DA, Gerson SA, Jarvik LF. Antidepressant drug treatment in the elderly. In Meitzer (Ed.) Psychopharmacology: the third generation of progress, pp. 1149–1158, Raven Press, New York, 1987
Potter WZ, Calil HM, Manian AA, Zavadil AP, Goodwin FK. Hydroxylated metabolites of tricyclic antidepressants. Biological Psychiatry 14: 601–613, 1979
Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. New England Journal of Medicine 325: 633–642, 1991
Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. Journal of Clinical Psychiatry 46: 276–277, 1985
Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. Journal of Clinical Psychopharmacology 10: 88–95, 1990
Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, et al. One-month prevalence of mental disorders in the United States. Archives of General Psychiatry 45: 977–986, 1988
Rickels K, Weise C, Case G, Hucker H. Tricyclic plasma levels in depressed outpatients treated with amitriptyline. Psychopharmacology 80: 14–18, 1983
Rockwell E, Lam RW, Zisook S. Antidepressant drug studies in the elderly. Psychiatric Clinics of North America 11: 215–233, 1988
Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, et al. Is doxepin a safer tricyclic for the heart? Journal of Clinical Psychiatry 52: 338–341, 1991
Rubin EH, Biggs JT, Preskorn SH. Nortriptyline pharmacokinetics and plasma levels: implications for clinical practice. Journal of Clinical Psychiatry 46: 418–424, 1985
Rudorfer MV, Potter WZ. Pharmacokinetics of antidepressants. In Meitzer (Ed.) Psychopharmacology: the third generation of progress, pp. 1353–1363, Raven Press, New York, 1987
Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clinical Pharmacokinetics 18: 346–364, 1990
Salzman C. A primer on geriatric psychopharmacology. American Journal of Psychiatry 139: 67–74, 1982
Schmucker DL. Aging and drug disposition: an update. Pharmacological Reviews 37: 133–148, 1985
Schneider LS, Cooper TB, Suckow RF, Lyness SA, Haugen C, et al. Relationship of hydroxynortriptyline to nortriptyline concentration and creatinine clearance in depressed elderly outpatients. Journal of Clinical Psychopharmacology 10: 333–337, 1990
Schulz P, Tumer-Tamiyasu K, Smith G, Giacomini KM, Blaschke TF. Amitriptyline disposition in young and elderly normal men. Clinical Pharmacology and Therapeutics 7: 360–366, 1983
Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clinical Pharmacology and Therapeutics 49: 18–23, 1991
Small GW. Recognition and treatment of depression in the elderly. Journal of Clinical Psychiatry 56 (No. 6, Suppl.): 11–22, 1991
Spar JE. Plasma trazodone concentrations in elderly depressed inpatients: cardiac effects and short-term efficacy. Journal of Clinical Psychopharmacology 7: 406–409, 1987
Thayssen P, Bjerre M, Kragh-Sørensen P, Møller M, Petersen OL, et al. Cardiovascular effects of imipramine and nortriptyline in elderly patients. Psychopharmacology 74: 360–364, 1981 1981
Thomsen K, Schou M. Renal lithium excretion in man. American Journal of Physiology 215: 823–827, 1968
Turbott J, Norman TR, Burrows GD, Maguire KP, Davies BM. Pharmacokinetics of nortriptyline in elderly volunteers. Communications in Psychopharmacology 4: 225–231, 1980
Uhlenhuth EH, Balter MB, Mellinger GD, Cisin I, Clinthorne J. Symptom checklist syndromes in the general population. Archives of General Psychiatry 40: 1167–1173, 1983
von Bahr C, Spina E, Bigersson C, Ericsson Ö, Göransson M, et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochemical Pharmacology 34: 2501–2505, 1985
Young RC, Alexopoulos GS, Shamoian CA, Kent E, Dhar AK, et al. Plasma 10-hydroxynortriptyline and ECG changes in elderly depressed patients. American Journal of Psychiatry 142: 866–868, 1985
Young RC, Alexopoulos GS, Shamoian CA, Manley MW, Dhar AK, et al. Plasma 10-hydroxynortriptyline in elderly depressed patients. Clinical Pharmacology and Therapeutics 35: 540–544, 1984
Ziegler VE, Biggs JT. Tricyclic plasma levels: effect of age, race, sex and smoking. Journal of the American Medical Association 238: 2167–2169, 1977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
von Moltke, L.L., Greenblatt, D.J. & Shader, R.I. Clinical Pharmacokinetics of Antidepressants in the Elderly. Clin. Pharmacokinet. 24, 141–160 (1993). https://doi.org/10.2165/00003088-199324020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199324020-00004